Paper Details

  1. Home
  2. Paper Details

A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.

Author: , ArnaizJoan A, GarcíaFelipe, GatellJosep M, González-CordónAna, InciarteAlexy, LagunoMontserrat, LealLorna, LeónAgathe, LuceroConstanza, MallolasJosep, ManzardoChristian, Martínez-RebollarMaría, PichJudit, RojasJhon, TorresBerta

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Maraviroc is a well-tolerated antiretroviral that can be used for post-exposure prophylaxis (PEP) in individuals with potential sexual exposure to HIV. PEP non-completion and adverse events were both significantly higher in patients allocated to ritonavir-boosted lopinavir.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: The objective of this study was to assess post-exposure prophylaxis (PEP) non-completion at day 28, comparing ritonavir-boosted lopinavir versus maraviroc, both with tenofovir disoproxil/emtricitabine as the backbone. METHODS: We conducted a prospective, open, randomized clinical trial....See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/jac/dkw048

データ提供：米国国立医学図書館（NLM）

Comparing Post-Exposure Prophylaxis Regimens for HIV: Maraviroc Shows Promise

Infectious diseases, a crucial area of medicine, seeks to understand and control the spread of infectious agents. HIV, a virus that can lead to AIDS, is a significant public health concern. This research compared the effectiveness of two post-exposure prophylaxis (PEP) regimens for preventing HIV infection.

Maraviroc Shows Superior Adherence and Tolerability

The study compared a regimen containing ritonavir-boosted lopinavir with a regimen containing maraviroc, both with tenofovir/emtricitabine as the backbone. The results showed that PEP non-completion at day 28 was significantly higher in the ritonavir-boosted lopinavir arm, suggesting that maraviroc may be a more tolerable and acceptable option for patients. Additionally, no seroconversions were observed in either group during the study.

Implications for HIV Prevention and Management

This research provides valuable insight into the effectiveness and tolerability of different PEP regimens for HIV prevention. The findings suggest that maraviroc may be a promising alternative for patients seeking PEP, potentially leading to improved adherence and outcomes. It's like choosing the right path in a desert: choosing a route that is more tolerable and manageable can increase the chances of reaching your destination.

Dr.Camel's Conclusion

This research highlights the potential of maraviroc as a valuable tool for HIV prevention. Like discovering a hidden oasis in a vast desert, this research provides a glimmer of hope for finding more effective and tolerable treatment options for HIV.

Date :
  1. Date Completed 2017-08-22
  2. Date Revised 2017-12-09
Further Info :

Pubmed ID

26994091

DOI: Digital Object Identifier

10.1093/jac/dkw048

Related Literature

Article Analysis
・Side Effects of maraviroc
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.